Ultragenyx Pharmaceutical Inc

2026. szept. 9. 20:02 UTC

Ultragenyx Pharmaceutical shares are declining as an investigation is initiated following the failure of its Phase 3 Aspire study for apazunersen.

2026. szept. 8. 20:04 UTC

Ultragenyx shares are lower after its Phase 3 Aspire trial for apazunersen failed to meet endpoints, prompting expense reductions and mixed analyst ratings.

2026. szept. 4. 20:02 UTC

Ultragenyx Pharmaceutical shares are higher today amid analyst updates, including Goldman Sachs lowering its price target to $19 and Barclays to $32.

2026. szept. 3. 20:03 UTC

Ultragenyx Pharmaceutical's stock is lower after its Phase 3 Aspire trial failed to meet primary endpoints, prompting analyst downgrades and expense reduction plans.

2026. szept. 2. 23:02 UTC

Ultragenyx Pharmaceutical shares are lower in after-market hours following the failure of its Phase 3 Aspire study for apazunersen in Angelman syndrome.

2026. szept. 1. 23:01 UTC

Ultragenyx Pharmaceutical Inc shares are lower in after-market trading despite positive Phase 3 data for GENGLYCOS, reflecting investor caution on FDA approval.

2026. aug. 31. 21:02 UTC

Ultragenyx Pharmaceutical Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment remains cautious amid Fed rate hike concerns.

2026. aug. 28. 22:56 UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, though they remain below their 20-day moving average after recent declines.

2026. aug. 26. 20:08 UTC

Ultragenyx Pharmaceutical granted 45,984 restricted stock units to new non-executive officers as part of its Employment Inducement Plan. Shares are trading roughly flat.

2026. aug. 25. 23:16 UTC

Ultragenyx Pharmaceutical granted nearly 46,000 restricted stock units to new hires, boosting shares in after-market trading amid ongoing strategic initiatives for rare diseases.

2026. aug. 24. 23:16 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reflecting a modest increase since Monday's close amid no specific news to explain the movement.

2026. aug. 22. 00:02 UTC

Ultragenyx Pharmaceutical shares are lower in after-market hours, with no specific news identified. The broader market has shown notable gains.

2026. aug. 21. 23:11 UTC

Ultragenyx Pharmaceutical shares moved higher in after-market trading, reflecting broader market gains despite the absence of specific company news.

2026. aug. 20. 23:46 UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, showing modest gains since Thursday's close, despite no specific news identified.

2026. aug. 19. 23:51 UTC

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

2026. aug. 18. 23:26 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market hours. No specific news was identified to explain the price movement.

2026. aug. 17. 23:51 UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, gaining traction despite broader market volatility from geopolitical tensions and rising crude oil prices.

2026. aug. 15. 00:06 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reaching a high of 2.96% following Friday's close amid broader economic concerns.

2026. aug. 14. 22:51 UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, advancing significantly since Friday's close amid easing expectations for Federal Reserve interest rate hikes.

2026. aug. 13. 19:16 UTC

Ultragenyx Pharmaceutical Inc. is declining, reflecting broader biotech sector weakness and a noted correlation with LABU's significant downturn.

2026. aug. 12. 22:16 UTC

Ultragenyx Pharmaceutical shares are higher in after-market trading, reflecting positive price movement amid a stable monetary policy outlook and recent inflation data.

2026. aug. 11. 19:36 UTC

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

2026. aug. 10. 19:16 UTC

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.

2026. aug. 7. 20:03 UTC

Ultragenyx Pharmaceutical reported a loss of -$0.90 per share, beating estimates. Revenue of $214 million also exceeded expectations, but shares are trading roughly flat.

2026. aug. 6. 23:21 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, showing unusual strength despite remaining below their 20-day moving average.

2026. aug. 5. 19:52 UTC

Ultragenyx shares are lower after Wells Fargo cut its price target to $45. The company reported an EPS loss of $0.90, exceeding expectations.

2026. aug. 4. 23:02 UTC

Ultragenyx Pharmaceutical reported second-quarter revenue of $214 million and narrowed its net loss to $92 million, with shares trading higher in after-market hours.

2026. aug. 3. 22:51 UTC

Ultragenyx Pharmaceutical shares are trading roughly flat after-market. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

2026. júl. 31. 19:52 UTC

Ultragenyx Pharmaceutical is lower today amid a decline in the Biotechnology sub-sector, with shares near the lower end of their one-month range.

2026. júl. 30. 19:58 UTC

Ultragenyx rises, supported by SPDR S&P Biotech ETF gains.